Progenics Pharmaceuticals Doses First Patient in Phase 2 Clinical Study of 1095 Radiotherapy for the Treatment of Metastatic Prostate Cancer Read more about Progenics Pharmaceuticals Doses First Patient in Phase 2 Clinical Study of 1095 Radiotherapy for the Treatment of Metastatic Prostate Cancer
Progenics Pharmaceuticals Announces Agreement with FUJIFILM Toyama Chemical Co. for Automated Bone Scan Index (aBSI) Product in Japan Read more about Progenics Pharmaceuticals Announces Agreement with FUJIFILM Toyama Chemical Co. for Automated Bone Scan Index (aBSI) Product in Japan
Progenics Pharmaceuticals to Initiate a Basket Trial by Year End to Support an Expanded Label for AZEDRA® (iobenguane I 131) in Multiple MIBG Avid Neuroendocrine Tumors Read more about Progenics Pharmaceuticals to Initiate a Basket Trial by Year End to Support an Expanded Label for AZEDRA® (iobenguane I 131) in Multiple MIBG Avid Neuroendocrine Tumors
Independent Readers Using Progenics’ PSMA AI Demonstrated a Statistically Significant Improvement of Accuracy, Speed, and Reproducibility Over Readers Without PSMA AI Read more about Independent Readers Using Progenics’ PSMA AI Demonstrated a Statistically Significant Improvement of Accuracy, Speed, and Reproducibility Over Readers Without PSMA AI
Data Presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting Highlights Potential of Progenics’ PSMA-Targeted Imaging Agent, PyL, in Detecting Prostate Cancer Read more about Data Presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting Highlights Potential of Progenics’ PSMA-Targeted Imaging Agent, PyL, in Detecting Prostate Cancer
Court Upholds The Validity And Determined Actavis' Infringement Of Patent Protecting RELISTOR® Tablets Read more about Court Upholds The Validity And Determined Actavis' Infringement Of Patent Protecting RELISTOR® Tablets
Progenics Doses First Patient in Pivotal Phase 3 Study of PyL, PSMA PET Imaging Agent, for the Detection of Prostate Cancer Read more about Progenics Doses First Patient in Pivotal Phase 3 Study of PyL, PSMA PET Imaging Agent, for the Detection of Prostate Cancer
Progenics Pharmaceuticals Announces Collaboration with Veterans Affairs on the AI Research Program for Medical Image Analysis Read more about Progenics Pharmaceuticals Announces Collaboration with Veterans Affairs on the AI Research Program for Medical Image Analysis
Progenics Pharmaceuticals Completes Enrollment in Pivotal Phase 3 CONDOR Study of PyL for the Detection of Prostate Cancer Read more about Progenics Pharmaceuticals Completes Enrollment in Pivotal Phase 3 CONDOR Study of PyL for the Detection of Prostate Cancer
CMS Grants New Technology Add-On Payment for Inpatient Use of AZEDRA® (iobenguane I 131) Read more about CMS Grants New Technology Add-On Payment for Inpatient Use of AZEDRA® (iobenguane I 131)
